Alpha 2.0
Login Register
» Authors » A Scott Paulson

A Scott Paulson

Explore the profile of A Scott Paulson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 137
Followers 0
Related Specialties
Oncology
Gastroenterology
General Medicine
Top 10 Co-Authors
Tanios Bekaii-Saab
Shubham Pant
Roberto Pazo Cid
Sreenivasa R Chandana
Zhimin Xiao
Eileen M OReilly
Christelle De La Fouchardiere
Richard A Hubner
Thorsten O Goetze
Fawzi Benzaghou
Published In
Cancer Gene Ther
Pancreas
Future Oncol
Cancer Invest
Gastric Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)
Wainberg Z, Melisi D, Macarulla T, Pazo Cid R, Chandana S, De La Fouchardiere C, et al.
Future Oncol . 2025 Feb; 21(7):765-774. PMID: 39935331
No abstract available.
2.
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Wainberg Z, Melisi D, Macarulla T, Pazo Cid R, Chandana S, De La Fouchardiere C, et al.
Lancet . 2023 Sep; 402(10409):1272-1281. PMID: 37708904
Background: Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine...
3.
Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices
Paulson A, Hess L, Liepa A, Cui Z, Aguilar K, Clark J, et al.
Gastric Cancer . 2018 Feb; 21(5):831-844. PMID: 29397460
Background: Limited real-world research has investigated ramucirumab for the treatment of patients with gastric or gastroesophageal junction (GEJ) cancer. This study was designed to describe ramucirumab monotherapy or combination therapy...
4.
Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States
Jiao X, Pulgar S, Boyd M, Braiteh F, Mirakhur B, Lowenthal S, et al.
Pancreas . 2017 Dec; 47(2):173-182. PMID: 29206668
Objective: This study was conducted to understand treatment patterns and clinical outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients treated in a large community oncology network. Methods: This retrospective study used...
5.
Systemic therapy for advanced carcinoid tumors: where do we go from here?
Paulson A, Bergsland E
J Natl Compr Canc Netw . 2012 Jun; 10(6):785-93. PMID: 22679120
Carcinoid tumors are relatively indolent, but the treatment of advanced disease remains a challenge. Liver-directed therapies are a consideration in patients with liver-dominant disease. Somatostatin analogs (SSTa) are routinely used...
6.
Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients
Nemunaitis J, Cunningham C, Vukelja S, Ruxer R, Adams N, Rich D, et al.
Cancer Invest . 2004 Oct; 22(3):360-7. PMID: 15493356
Purpose: To determine maximum tolerated dose (MTD) and evidence of antitumor activity of topotecan in combination with gemcitabine in refractory cancer patients. Methods: This was a Phase I, prospective, dose-escalation...
7.
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
Nemunaitis J, Cunningham C, Tong A, Post L, Netto G, Paulson A, et al.
Cancer Gene Ther . 2003 Apr; 10(5):341-52. PMID: 12719704
ONYX-015 is an adenovirus that selectively replicates in p53 dysfunctional or mutated malignant cells. We performed a pilot trial to determine the safety and feasibility of treatment with ONYX-015 delivered...